References
- Torrance G, Siegel J, Luce B. Framing and designing the cost-effectiveness analysis. In: Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
- US Congress. Office of Technology Assessment, Tools for evaluating health technologies: five background papers, BP-I-I-142. US Government Printing Office, Washington DC, USA (1995).
- Hylan TR. Kotsanos JG, Overhage JM etal Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. Am.Man. Care 2, 1211–1223 (1996).
- Lubek D. The economic impact of arthritis. Arthritis Care Res. 8, (1995).
- Gabriel S, Crowson C, Campion M, OTallom WM. Direct medical costs unique to people with arthritis. J. Rheumatol 24, 719–725 (1997).
- McIntosh E. The cost of rheumatoid arthritis. BE .1. Rheum. 35, 781–790 (1996).
- Lanes S, Lanza L, Radensky P etal Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance ofdrug and surgery costs. Arthritis Rheum. 40, 1475–1481 (1997).
- Yelin E, Wanke L. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209–1218 (1999).
- Fries JF, Spitz P, Kraines RG, Hollman HR. Measurement of patient outcome in arthritis. Arthritis kreum. 23, 137–145 (1980). roBruce B, Fries JF: The Stanford Health Assessment Questionnaire: a review of its history, issues progress and documentation. J. Rheumatol 30, 167–178 (2003).
- Goldsmith C, Boers M, Bombardier C, Tugwell P for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. I Rheumatol 20, 561–565 (1993).
- Wells G, Tugwell P, Kraag G, Baker P Groh J, Redelmeier D. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. Rheumatol 20, 557–560 (1993).
- Evans C, Crawford B. Data collection methods in prospective economic evaluations: how accurate are the results? Value Health 3, 277–286 (2000). Reviews the accuracy of resource use estimates based on data from prospective trials.
- Ellis C, Drake L, Prendergast M eta]. Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema. PharmacoEconornics21, 875–883, (2003).
- O'Brien B. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire trials. Med. Care 34, D599—D5108 (1996). Overview of the problems associated with conducting piggyback studies.